Cargando…

Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature

Neuroendocrine tumors (NETs) of the lung are well-differentiated neuroendocrine neoplasms (NENs) with a heterogeneous clinical behaviour. Unlike gastroenteropancreatic NENs where therapeutic armamentarium clearly increased over the last decade, everolimus represented the only clinical practical inno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peri, Marta, Fazio, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355078/ https://www.ncbi.nlm.nih.gov/pubmed/32753993 http://dx.doi.org/10.2147/LCTT.S249928

Ejemplares similares

Endocrine and Neuroendocrine Tumors: A Special Issue
por: Berruti, Alfredo, et al.
Publicado: (2022)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis
por: Fazio, Nicola, et al.
Publicado: (2017)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
por: Oberstein, Paul E., et al.
Publicado: (2012)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors
por: Berardi, Rossana, et al.
Publicado: (2017)

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus
por: Cen, Putao, et al.
Publicado: (2012)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
por: Vitali, Eleonora, et al.
Publicado: (2020)

CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors
por: Caruso, Damiano, et al.
Publicado: (2022)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review
por: Chang, Shih-Chun, et al.
Publicado: (2021)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report
por: Kaiho-Sakuma, Michiko, et al.
Publicado: (2018)

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
por: Wetz, Christoph, et al.
Publicado: (2020)

Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes
por: Cella, Chiara Alessandra, et al.
Publicado: (2022)

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms
por: Kurita, Yusuke, et al.
Publicado: (2022)

Watch and wait policy in advanced neuroendocrine tumors: What does it mean?
por: Fazio, Nicola
Publicado: (2017)

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
por: Yao, James C, et al.
Publicado: (2019)

Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma
por: Fonseca, Paula J., et al.
Publicado: (2013)

A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor
por: Sato, Asahi, et al.
Publicado: (2017)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
por: Palmer, Jayne, et al.
Publicado: (2020)

Bone metastases from neuroendocrine tumors: clinical and biological considerations
por: Scopel, Matteo, et al.
Publicado: (2022)

Cryolipolysis: patient selection and special considerations
por: Meyer, Patricia Froes, et al.
Publicado: (2018)

Lung transplantation in chronic obstructive pulmonary disease: patient selection and special considerations
por: Lane, C Randall, et al.
Publicado: (2015)

Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus
por: Frankel, Arthur E., et al.
Publicado: (2021)

Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Tympanostomy tubes: patient selection and special considerations
por: Whittemore, Kenneth R
Publicado: (2015)

Technical Considerations in Stereotactic Ablative Radiotherapy for Localized Neuroendocrine Cancer of the Lung: Case Report and Review of the Literature
por: Callan, Laura, et al.
Publicado: (2018)

Neuroendocrine Tumors of the Lung
por: Fisseler-Eckhoff, Annette, et al.
Publicado: (2012)

Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
por: Kim, Eui Joo, et al.
Publicado: (2020)

Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report
por: Abe, Kentaro, et al.
Publicado: (2023)

Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report
por: Sibertin-Blanc, Camille, et al.
Publicado: (2013)

Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
por: Kurita, Yusuke, et al.
Publicado: (2022)

A Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations
por: Kim, Shin Young, et al.
Publicado: (2014)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis
por: Ranallo, Nicoletta, et al.
Publicado: (2022)

Special considerations for pediatric vitreoretinal surgery
por: Gan, Nicola Y., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iph8s56qjj5o0cl08q1vsvlpj3